Remicade (Infliximab) Denied: Fighting Forced Biosimilar Switching to Inflectra, Renflexis, and Avsola

Remicade (infliximab) is a chimeric TNF inhibitor administered as an IV infusion, FDA-approved for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis. It has been in use since 1998 and has a well-established safety and efficacy profile across all its indications. With multiple biosimilars now on the market — Inflectra (infliximab-dyyb), Renflexis (infliximab-abda), Avsola (infliximab-axxq), and Ixifi (infliximab-qbtx) — insurance companies and pharmacy benefit managers have aggressively moved to force switches from brand Remicade, sometimes mid-infusion course.

Why Remicade Is Denied

Biosimilar mandatory substitution policies. The most common scenario today is that an insurer has removed brand Remicade from its formulary or placed it on a tier requiring massive cost-sharing, effectively forcing patients onto a biosimilar. Unlike pharmacy biosimilars, infliximab biosimilars are administered in infusion centers, making the switch operationally complex.

Step therapy before biologics. For new prescriptions, the usual step therapy requirements apply: conventional DMARDs for RA and PsA, NSAIDs for AS, 5-ASA and immunomodulators for IBD, topical therapies and systemics for psoriasis. These must be documented in the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization.

Infusion benefit vs. pharmacy benefit confusion. Remicade is administered intravenously and is typically covered under the medical benefit (Part B in Medicare, medical plan benefit for commercial insurance), not the pharmacy benefit. Denials sometimes occur because the PA was submitted under the wrong benefit, or because the infusion facility is out-of-network. This administrative denial type is quickly resolved by resubmitting under the correct benefit.

Dose escalation denials. Many Remicade patients require dose escalation over time due to secondary loss of response. Insurers may deny escalated doses (above the label starting dose) as not medically necessary. For Crohn's disease and UC patients, dose optimization is standard clinical practice and is supported by guidelines.

Non-Medical Switching Laws: Your Most Important Defense

If you are a patient who has been stable on brand Remicade and your insurer is requiring you to switch to a biosimilar without a clinical reason, you have significant legal protections in many states.

What non-medical switching laws say. Many states have enacted laws prohibiting insurers from requiring patients to switch from a medication that is currently controlling their disease to a different medication based solely on formulary changes, contract changes, or cost considerations. These laws typically require:

• Insurer notification to the prescriber of the switch request
• A process for the prescriber to certify that the switch is clinically inappropriate
• Continuation of the current drug while the appeal is pending

How to invoke these protections. Have your gastroenterologist, rheumatologist, or other prescribing physician send a non-medical switching objection letter to the insurer stating:

• The patient is clinically stable on brand infliximab
• The switch is not clinically indicated
• Switching carries risks of immunogenicity (development of anti-infliximab antibodies) that could render future infliximab products, including biosimilars, ineffective
• The physician objects to the switch under applicable state law

Immunogenicity argument. Remicade is a chimeric (mouse-human) protein that triggers anti-drug antibody (ADA) development in a significant percentage of patients. Combined immunosuppression (e.g., with azathioprine or methotrexate) reduces ADA formation. If a patient's regimen includes immunomodulator co-therapy specifically to reduce immunogenicity to their current infliximab product, switching biosimilar manufacturers could affect the immunological balance. This is a legitimate clinical concern your prescriber can document.

Dose Escalation Appeals

If your dose was escalated from 5 mg/kg to 10 mg/kg Q6W or Q4W (common in IBD), the appeal should include:

• Documentation of secondary loss of response (worsening disease activity scores, rising fecal calprotectin, worsening endoscopic findings)
• Infliximab trough level testing confirming low drug levels rather than high antibody titers (drug levels guide the decision to escalate dose vs. switch agents)
• Your prescriber's clinical rationale for dose escalation vs. switching to a different drug class

Fight Back With ClaimBack

Forced infliximab biosimilar switching mid-therapy is one of the clearest cases for appeal available in specialty medication coverage disputes. Non-medical switching laws, immunogenicity science, and clinical stability arguments combine to make these cases winnable. ClaimBack builds that appeal for you.

Start your Remicade appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: What's the Difference?
• Common Reasons Insurance Claims Are Denied